Zoryve Seeks Expansion Into Infant and Toddler Atopic Dermatitis as Non-Steroidal Topical Therapy Moves to Younger Ages
Arcutis is pushing a PDE4 inhibitor that has already gained a foothold in the dermatology market into infants and toddlers aged 3 to 24 months; if cleared by the FDA, the significance would extend beyond commercial reach to a redistribution of available options for the youngest patients.